Published on: November 9, 2021




UK drug regulator announced that it has approved the first oral antiviral for treatment of Covid-19. The drug, molnupiravir, has been developed by Merck and Ridgeback


  • Developed initially to treat influenza
  • Has been repurposed to treat Covid patients
  • Interferes with the replication of SARS-CoV-2, thereby reducing severity of disease.
  • Most effective when used early
  • UK has recommended its use as soon as possible following a positive test and within five days of symptoms onset.